The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.
 
Neha Mehta-Shah
Consulting or Advisory Role - C4 Therapeutics; Daiichi Sankyo/UCB Japan; Karyopharm Therapeutics; Kyowa Hakko Kirin; Kyowa Kirin International; Ono Pharmaceutical; Secura Bio
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Innate Pharma (Inst); Verastem (Inst)
 
Susan Michelle Geyer
No Relationships to Disclose
 
Stefan K. Barta
Honoraria - Acrotech Biopharma; Affimed Therapeutics; Daiichi Sankyo/Lilly; Kyowa Kirin International; Seagen
 
Jennifer Effie Amengual
Honoraria - Daiichi Sankyo; Janssen; Karyopharm Therapeutics
Research Funding - Appia Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Epizyme
 
Travis Dockter
No Relationships to Disclose
 
Chadwick Wright
No Relationships to Disclose
 
Shira Dinner
No Relationships to Disclose
 
Eric D. Hsi
Consulting or Advisory Role - Astellas Oncology; CytomX Therapeutics
Research Funding - Lilly (Inst)
 
Nancy L. Bartlett
Consulting or Advisory Role - Acerta Pharma; ADC Therapeutics; BTG; Roche/Genentech; Seagen
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Steven M. Horwitz
Consulting or Advisory Role - Acrotech Biopharma; ADC Therapeutics; Astex Pharmaceuticals; C4 Therapeutics; Celgene; Janssen Oncology; Kura Oncology; Kyowa Hakko Kirin; Millennium; Myeloid Therapeutics; Ono Pharmaceutical; Seagen; Secura Bio; Shoreline Biosciences; Takeda; Trillium Therapeutics; Tubulis GmbH; Verastem; Vividion Therapeutics
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Aileron Therapeutics (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Forty Seven (Inst); Kyowa Hakko Kirin (Inst); Seagen (Inst); Secura Bio (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Verastem (Inst)
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Genentech; Genmab; Incyte; Janssen; Kite/Gilead; MEI Pharma; MorphoSys; Pharmacyclics; Roche
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Celgene (Inst); Genentech (Inst)
 
Jonathan W. Friedberg
Research Funding - Enterome (Inst)
Patents, Royalties, Other Intellectual Property - Patient on bone marrow microenvironment signals (I)
 
John Paul Leonard
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Akcea Therapeutics; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Incyte; Janssen Oncology; Karyopharm Therapeutics; MEI Pharma; Merck; Miltenyi Biotec; Morphosys; MustangBio; Nordic Nanovector; Nordic Nanovector; Regeneron; Sandoz; Second Genome; Sutro Biopharma
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Celgene (Inst); Epizyme (Inst); Genentech (Inst); Janssen Oncology (Inst); National Cancer Institute (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - BeiGene